Resveratrol in cancer management: where are we and where we go from here?
Resveratrol in cancer management: where are we and where we go from here?
复制标题
DOI：
10.1111/j.1749-6632.2010.05851.x
复制
发表时间：
2011-01-01
期刊：
影响因子：
--
通讯作者：
Ahmad, Nihal
中科院分区：
文献类型：
--
作者：
Ndiaye, Mary;Kumar, Raj;Ahmad, Nihal
白藜芦醇已被证明对几种疾病具有保护作用。大量研究表明，白藜芦醇具有预防和治疗癌症的作用。然而，白藜芦醇用于疾病治疗的未来发展的一个重要问题是，由于其在哺乳动物中的快速代谢，其生物利用度较低。因此，需要努力提高其在人体内的生物利用度。在这个方向上，一些可能的方案包括通过与能够抑制白藜芦醇体内代谢的药物的新颖的基于机制的组合来提高白藜芦醇的生物利用度，纳米颗粒介导的给药，使用自然产生的或合成的白藜芦醇类似物，以及使用白藜芦醇的结合代谢物，尽管这些需要仔细评估，因为它们可能需要在目标器官从白藜芦醇中分离出来才能引起生物反应。因此，需要协调一致和多学科的努力才能将瑞血曲尔提升到下一个水平，也就是从“病床到床边”。
Resveratrol has been shown to afford protection against several diseases. A plethora of studies have suggested that resveratrol imparts cancer chemopreventive and therapeutic responses. However, an important issue with the future development of resveratrol for disease management is its low bioavailability due to its rapid metabolism in mammals. Therefore, efforts are needed to enhance its bioavailability in humans. In this direction, some possible scenarios include enhancing the bioavailability of resveratrol by novel mechanism-based combinations with agents that can inhibit the in vivo metabolism of resveratrol, nanoparticle-mediated delivery, use of naturally occurring or synthetic analogues of resveratrol, and use of conjugated metabolites of resveratrol, though these need to be carefully evaluated as they may need to be deconjugated from resveratrol at the target organ to elicit a biological response. Thus, concerted and multidisciplinary efforts are needed to take reseratrol to the next level, that is, from the "bench-to-bedside."